针刺联合美多巴治疗帕金森病的系统评价与Meta分析
该系统评价纳入11项RCT共831例受试者,比较针刺联合美多巴与单用美多巴治疗帕金森病的疗效与安全性。Meta分析显示联合治疗可提高临床有效率(RR=1.28,95%CI 1.18~1.38,P<0.001),改善UPDRS II及UPDRS I-IV总分,并减少胃肠道反应、开关现象和精神障碍等不良反应,但多数纳入研究质量较低,结论需谨慎解读。
要点
- 针刺联合美多巴较单用美多巴提高帕金森病临床有效率(RR=1.28,95%CI 1.18~1.38)。
- 联合治疗改善UPDRS II及UPDRS I-IV总分,但对UPDRS I、III、IV单项无显著改善。
- 联合治疗减少胃肠道反应、开关现象和精神障碍,未显著减少运动障碍。
核心结论
- 针刺联合美多巴在一定程度上可提高帕金森病的临床有效性和安全性,但鉴于多数纳入研究质量较低,结论需谨慎看待。
研究设计与样本
- 系统评价与Meta分析,检索1995年4月至2015年4月发表的针刺联合美多巴治疗帕金森病的随机对照试验,最终纳入11项RCT共831例受试者。
主要发现
- 针刺联合美多巴较单用美多巴显著提高临床有效率(RR=1.28,95%CI 1.18~1.38,P<0.001)。
- 联合治疗显著改善UPDRS II评分(SMD=-1.00,95%CI -1.71~-0.29,P=0.006)及UPDRS I-IV总分(SMD=-1.15,95%CI -1.63~-0.67,P<0.001)。
- 联合治疗对UPDRS I(SMD=-0.37,95%CI -0.77~0.02,P=0.06)、UPDRS III(SMD=-0.93,95%CI -2.28~0.41,P=0.17)、UPDRS IV(SMD=-0.78,95%CI -2.24~0.68,P=0.30)评分无显著改善。
- 联合治疗显著减少胃肠道反应(RR=0.38,95%CI 0.23~0.65,P<0.001)、开关现象(RR=0.27,95%CI 0.11~0.66,P=0.004)和精神障碍(RR=0.24,95%CI 0.06~0.92,P=0.04),但未显著减少运动障碍(RR=0.64,95%CI 0.35~1.16,P=0.14)。
关键数值与推荐
- 主要结局为总有效率,次要结局为UPDRS评分,效应量以RR或SMD及95%CI表示。
临床怎么用
- 在帕金森病治疗中,可考虑针刺联合美多巴以改善日常活动能力和总体状况,并减少胃肠道反应、开关现象和精神障碍等不良反应。
- 对精神活动、行为、情绪及运动障碍的改善,联合治疗未显示优于单用美多巴,应结合患者具体情况个体化决策。
局限性
- 多数纳入研究质量较低,结论需谨慎解读。
- 需要更多高质量、多中心、前瞻性、大样本随机对照试验进一步明确针刺联合美多巴治疗帕金森病的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness and safety of acupuncture combined with Madopar for the treatment of Parkinson's disease (PD), compared to the use of Madopar alone. METHODS: A systematic search was carried out for randomised controlled trials (RCTs) of acupuncture and Madopar for the treatment of PD published between April 1995 and April 2015. The primary outcome was total effectiveness rate and secondary outcomes included Unified Parkinson's Disease Rating Scale (UPDRS) scores. Data were pooled and analysed with RevMan 5.3. Results were expressed as relative ratio (RR) with 95% confidence interval (CIs). RESULTS: Finally, 11 RCTs with 831 subjects were included. Meta-analyses showed that acupuncture combined with Madopar for the treatment of PD can significantly improve the clinical effectiveness compared with Madopar alone (RR=1.28, 95% CI 1.18 to 1.38, P<0.001). It was also found that acupuncture combined with Madopar significantly improved the UPDRS II (SMD=-1.00, 95% CI -1.71 to -0.29, P=0.006) and UPDRS I-IV total summed scores (SMD=-1.15, 95% CI -1.63 to -0.67, P<0.001) but not UPDRS I (SMD=-0.37, 95% CI -0.77 to 0.02, P=0.06), UPDRS III (SMD=-0.93, 95% CI -2.28 to 0.41, P=0.17) or UPDRS IV (SMD=-0.78, 95% CI -2.24 to 0.68, P=0.30) scores. Accordingly, acupuncture combined with Madopar appeared to have a positive effect on activities of daily life and the general condition of patients with PD, but was not better than Madopar alone for the treatment of mental activity, behaviour, mood and motor disability. In the safety evaluation, it was found that acupuncture combined with Madopar was associated with significantly fewer adverse effects including gastrointestinal reactions (RR=0.38, 95% CI 0.23 to 0.65, P<0.001), on-off phenomena (RR=0.27, 95% CI 0.11 to 0.66, P=0.004) and mental disorders (RR=0.24, 95% CI 0.06 to 0.92, P=0.04) but did not significantly reduce dyskinesia (RR=0.64, 95% CI 0.35 to 1.16, P=0.14). CONCLUSION: Acupuncture combined with Madopar appears, to some extent, to improve clinical effectiveness and safety in the treatment of PD, compared with Madopar alone. This conclusion must be considered cautiously, given the quality of most of the studies included was low. Therefore, more high-quality, multicentre, prospective, RCTs with large sample sizes are needed to further clarify the effect of acupuncture combined with Madopar for PD.
引用
- Liu H, Chen L, Zhang Z, et al. Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis. Acupunct Med. 2017. PMID: 29180347. doi:10.1136/acupmed-2016-011342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。